Bone repair stem cell therapy - Forticell Bioscience

Drug Profile

Bone repair stem cell therapy - Forticell Bioscience

Alternative Names: fibrin-microbead

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Ortec International
  • Class
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Fracture

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Fracture in USA (Intralesional, Implant)
  • 10 Jan 2008 Ortec International is now called Forticell Bioscience
  • 22 Jun 2006 Preclinical trials in Bone regeneration in USA (Implant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top